Details for New Drug Application (NDA): 209803
✉ Email this page to a colleague
The generic ingredient in STEGLATRO is ertugliflozin. Two suppliers are listed for this compound. Additional details are available on the ertugliflozin profile page.
Summary for 209803
Tradename: | STEGLATRO |
Applicant: | Msd Sub Merck |
Ingredient: | ertugliflozin |
Patents: | 1 |
Suppliers and Packaging for NDA: 209803
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
STEGLATRO | ertugliflozin | TABLET;ORAL | 209803 | NDA | Merck Sharp & Dohme LLC | 0006-5363 | 0006-5363-03 | 30 TABLET, FILM COATED in 1 BOTTLE (0006-5363-03) |
STEGLATRO | ertugliflozin | TABLET;ORAL | 209803 | NDA | Merck Sharp & Dohme LLC | 0006-5363 | 0006-5363-06 | 90 TABLET, FILM COATED in 1 BOTTLE (0006-5363-06) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
Approval Date: | Dec 19, 2017 | TE: | AB | RLD: | Yes | ||||
Regulatory Exclusivity Expiration: | Sep 17, 2024 | ||||||||
Regulatory Exclusivity Use: | REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jul 13, 2030 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Patented Use: | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 15MG | ||||
Approval Date: | Dec 19, 2017 | TE: | AB | RLD: | Yes | ||||
Regulatory Exclusivity Expiration: | Sep 17, 2024 | ||||||||
Regulatory Exclusivity Use: | REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV |
Complete Access Available with Subscription